Cabaletta Bio, Cellares report 10-year commercial supply agreement for rese-cel

Cabaletta Bio (CABA) and Cellares announced a commercial agreement to supply resecabtagene autoleucel using Cellares’ automated Cell Shuttle and through future implementation of Cellares’ Cell Q platform. The companies believe Cellares’ automated platforms for manufacturing and QC release can enable flexible low-cost scaling of commercial production of rese-cel to thousands of batches per year with minimal capital investment. Under the agreement, Cellares is expected to provide future commercial supply of rese-cel, pending FDA approval, using its automated manufacturing and quality control platforms. Under the terms of the agreement, Cabaletta has secured the ability to supply thousands of batches per year over a 10-year period with minimal capital investment. The companies anticipate the per batch cost to be among the lowest in the industry for autologous cell therapy production.